ELOCTA 2000 IU Powder and solvent for solution for injection

DRUG2 trials

Sponsors

Swedish Orphan Biovitrum AB (publ), F. Hoffmann-La Roche AG

Conditions

Hemophilia A and BType 3 Von Willebrand Disease

Phase 3

A Phase III, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Prophylaxis in Patients with Type 3 Von Willebrand Disease

RecruitingCTIS2024-515622-80-00

F. Hoffmann-La Roche AGType 3 Von Willebrand Disease

Start: 2025-06-04Target: 47Updated: 2025-06-27

Phase 4

An 18-month low-interventional prospective, multicentre study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa

CompletedCTIS2022-502921-16-00

Swedish Orphan Biovitrum AB (publ)Hemophilia A and B

Start: 2023-07-21End: 2023-12-01Target: 247Updated: 2023-10-16